Separate names with a comma.
Christian Angermayer • Following • Following Founder bei Apeiron Investment GroupFounder bei Apeiron Investment Group 1d • 1 day ago...
Plus the Earnings Webcast: https://edge.media-server.com/mmc/p/846ghfnx/ You can just fill in the form to listen to the replay for 30 more days....
I suggest those commenting recently watch this interview: [MEDIA] It will answer a lot of questions.
Blackrock now owns 7% of MNMD https://ir.stockpr.com/mindmed/sec-filings-email/content/0002012383-24-003562/ca60255c8850_110824.txt
RFK Jr. Pledges To Legalize Marijuana And Psychedelics, Using Revenue To Fund Farms Where People Recovering From Drug Addiction Can Grow Organic...
MindMed Reports Third Quarter 2024 Financial Results and Business Updates --On track to initiate the Phase 3 Voyage study of MM120 Orally...
Up 12.5%! During his first term, Trump emphasized deregulation and aimed to streamline the drug approval process through initiatives like the...
Functional and Sexual Disability, and Quality of Life After One Dose of MM120 (Lysergide) in Adults With Generalized Anxiety Disorder...
Can LSD break the 20-year drought in anxiety treatment? As MindMed advances its novel LSD therapy to a Phase 3 trial, the company aims to...
Not overly concerned - they have cash runway to 2027... trials end in 2026... if FDA approval happens in 2026 this will explode.
Psychedelics and the Future of Anxiety Relief [MEDIA]
Bank of New York Mellon Corp Purchases 203,216 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)...
Fireside chat at the 2024 Cantor Global Healthcare Conference with Robert Barrow, and CMO Dan Karlin...
After the Lykos debacle, what’s next for psychedelic therapies? While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic...
That's what I am thinking.
Several potential signals with the recent Employee Inducement Grants for MindMed I want to go over three areas. 1; what is the outlook for...
This study explored pharmacological and extra-pharmacological predictors of the LSD experience. While dose emerged as the most influential...
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants https://www.nature.com/articles/s41398-024-03074-9
back at pre fda announcement levels. Accumulation zone for me. Perfect entry time for the next wave up. price action will be incredible as we...
H.C. Wainwright adjusted its outlook on MindMed (NASDAQ:MNMD) stock, increasing the price target to $55 from the previous $35 while reaffirming a...
